A former pharmaceutical executive traded on nonpublic information about an antipsychotic drug’s development, avoiding $1.3 ...

The Nasdaq has had a challenging start to 2025, with the index dropping nearly 12% YTD, as of March 13. March 10 marked its worst single-day decline in almost two years, plunging 4% as investor ...

George Demos, former vice president of drug safety and pharmacovigilance at Acadia Pharmaceuticals Inc., is the latest biopharma executive to plead guilty to insider trading charges. BioWorld ...

SAN DIEGO - Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), a $2.9 billion market cap neuroscience company with strong financial health according to InvestingPro data, has granted inducement awards to ...

ACADIA Pharmaceuticals Inc. continues to navigate a complex market environment, balancing the growth of its established products with the development of its pipeline. Trading at an EV/EBITDA ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on central nervous system disorders, has been navigating a complex market landscape with its key products NUPLAZID and ...

Use the dropdown to select a relevant stock exchange for the current NASDAQ ACAD share price (ISIN: US0042251084) to enhance your trading decisions with our free investment tools and resources. What ...

MARINUS PHARMACEUTICALS ($MRNS) is expected to release its quarterly earnings data on Tuesday, March 11th after market close, per Finnhub. Analysts are expecting ...